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Abstract 
Background and Purpose – Long-term outcome after subarachnoid hemorrhage (SAH) is 
potentially linked to cytotoxic heme. Free heme is bound by hemopexin (Hpx) and rapidly 
scavenged by CD91. We hypothesized that heme scavenging in the brain would be associated 
with outcome after haemorrhage.  
Methods - Using cerebrospinal fluid (CSF) and tissue from SAH patients and control 
individuals, the activity of the intracranial CD91-Hpx system was examined using enzyme-
linked immunoassays, ultra-high performance liquid chromatography and 
immunohistochemistry.  
Results - In control individuals, CSF Hpx was mainly synthesized intrathecally. After SAH, 
CSF Hpx was high in one-third of cases, and these patients had a higher probability of 
delayed cerebral ischaemia and poorer neurological outcome. The intracranial CD91-Hpx 
system was active after SAH since CD91 positively correlated with iron deposition in brain 
tissue. Heme-Hpx uptake saturated rapidly after SAH, since bound heme accumulated early 
in the CSF. When the blood-brain barrier was compromised following SAH, serum Hpx level 
was lower, suggesting heme transfer to the circulation for peripheral CD91 scavenging.  
Conclusions - The CD91-heme-Hpx scavenging system is important after SAH and merits 
further study as a potential prognostic marker and therapeutic target. 
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Introduction 
 
SAH is an example of extravascular haemolysis with a high mortality and morbidity, and 
associated economic cost. Following haemolysis, cell-free Hb undergoes oxidation to 
methemoglobin, which through a number of hemichrome intermediates, finally degrades into 
a denatured globin protein and the redox-active heme moiety (iron-protoporphyrin IX). Due 
to a combination of redox activity and lipophilicity, free heme is toxic in a number of ways; 
including, covalent modification of substrates, intercalation in the lipid bilayer and lipid 
peroxidation, which perturbs membrane homeostasis to cause cellular dysfunction and cell 
death.1 Hpx neutralizes the redox toxicity of heme by formation of the heme-Hpx complex, 
which prevents heme from generating free radical reactions2, and leads to its uptake by 
CD91.3 The CD163-haptoglobin system is the body’s first line of defence during haemolysis, 
but this system is saturated after SAH, and free Hb is detectable in the CSF.4 In this situation, 
the CD91-Hpx system is likely to be important. 
 
Hpx is an abundant plasma protein, also expressed by neurones and glia.5 The relative 
contribution of these two sources to human CSF Hpx is unknown. Also, the response of the 
human Hpx-CD91 scavenging system to subarachnoid hemorrhage has not been studied. This 
study addresses these questions by analysing CSF and brain tissue from patients after SAH 
and controls.  
 
Materials and Methods 
 
Clinical Studies. Participants were recruited after referral to tertiary centres in Manchester, 
Birmingham, Southampton and Cambridge, with respective Research Ethical Committee 
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approvals. The characteristics of control participants (n=20) and SAH patients (n=30) in the 
main study are listed in Table I (online-only Data Supplement).  CSF in patients with SAH 
was obtained from external ventricular drains. Control participants were patients with non-
inflammatory / non-haemorrhagic conditions who underwent lumbar puncture and were 
subsequently found to have normal CSF with respect to protein, glucose, cell count, cytology, 
albumin CSF/serum quotient and isoelectric focusing for oligoclonal bands. Seven SAH 
patients were recruited to Clinical Study 2, to enable further analysis of heme, which required 
more CSF (Table II, online-only Data Supplement). Heme quantitation was performed using 
an in-house validated ultra-high performance liquid chromatography (UPLC) technique; 
established immunoassays were used for Hpx and albumin (online-only Data Supplement). 
 
Post-mortem study. Post-mortem brain tissue from SAH (n=7) and matched control (n=5) 
cases was obtained from the University Hospital Southampton NHS Foundation Trust as part 
of the UK Brain Archive Information Network (BRAIN UK). Tissue sections were selected 
close to the bleed, so anatomical region varied in individual cases. The mean SAH-to-death 
interval was 16 days (range 11-25 days); further characteristics are available in the online-
only Data Supplement. CD91 and iron were analysed by immunohistochemistry and Perls 
staining respectively. See online-only Data Supplement for more details. 
 
Statistical analysis. The distribution of each dataset was assessed, and parametric or non-
parametric tests were employed accordingly, as indicated in the text. Statistical tests were 
conducted at the 5% two-sided significance level using SPSS v21. 
 
Results 
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Hemopexin is mainly produced intrathecally in control CSF. The CSF Hpx reference 
range as determined by enzyme-linked immunosorbent assay was 12.3 to 32.6µg/ml; the 
mean concentration was 22.4µg/ml. There was no gender difference (means of 21.5µg/ml and 
24.6µg/ml in females and males respectively, p=0.23, unpaired t-test). A well-established and 
accepted technique to determine intrathecal synthesis of blood-derived proteins similar to 
albumin is the intrathecal index, defined as the CSF/serum ratio of Hpx (QHpx) divided by the 
CSF/serum ratio of albumin (Qalb).6 Albumin is a plasma protein which is not synthesized in 
brain and is wholly derived from plasma via diffusion across the blood-brain barrier (BBB). 
With a molecular weight of 69 kDa and a molecular size of 25.6 Å, albumin has the 
appropriate biophysical parameters to act as a reference protein for the diffusion of Hpx 
across the BBB (Hpx: molecular weight of 68 kDa; molecular size of 36 Å). QHpx was 
significantly greater than Qalb (p<0.0001, Wilcoxon test, Figure 1A); the intrathecal index 
(QHpx/Qalb) was 10.5. Thus the vast majority of Hpx is produced intrathecally in control 
individuals, with only about one tenth being derived from the circulation. 
 
The CD91-hemopexin heme scavenging system is present and active in human brain 
after SAH. CD91 immunohistochemistry on human brain tissue revealed expression in 
neurons and glia (Figure 1B). Uptake of heme-Hpx complexes leads to intracellular 
deposition of heme’s iron moiety.7 Perls staining to quantify iron deposition revealed a 
significantly greater deposition of iron in SAH versus control cases (p=0.028, Mann-Whitney 
test, Figure 1C). Regardless of whether there was blood clot in the sections, iron deposition 
significantly correlated with CD91 (Spearman r=0.79, p=0.0025, Figure 1D), indicating that 
the CD91-Hpx system actively scavenges heme after SAH. 
 
6 
 
Increased CSF hemopexin after SAH is associated with poor outcome. After SAH, CSF 
Hpx had a bimodal distribution; in 30% of patients (n=9/30), CSF Hpx was above the 
reference range (Figure 2A). In high versus normal CSF Hpx patients, delayed cerebral 
ischaemia (DCI) occurred more frequently and neurological outcome six months after SAH, 
as assessed by the modified Rankin Scale (mRS), was poorer (DCI: 57% versus 11%, 
p=0.028, Fisher exact test; mean mRS: 5.0 versus 2.4, p=0.025, unpaired t-test). The 
difference in Glasgow Outcome Scale (GOS) was not statistically significant (mean 2.5 
versus 3.9, p=0.122, unpaired t-test).   The difference in outcome between high and normal 
CSF Hpx groups could not be explained by a number of other factors related to bleed size or 
severity (Table III, online-only Data Supplement). Although more females than males had a 
high CSF Hpx, this was not significant, and CSF Hpx was not significantly different between 
the sexes (25.2µg/ml and 23.3µg/ml in females and males respectively, p=0.699, Mann-
Whitney test). Overall, this indicates that CSF Hpx level is associated with outcome after 
SAH, and may be a potentially useful prognostic marker, independent of bleed size.  
 
Source of increased CSF hemopexin after SAH. The seven-fold increase in CSF Hpx 
(Table III, online-only Data Supplement), could be blood or brain-derived. QHpx was 
significantly raised in high CSF Hpx patients (three-fold, p<0.001, unpaired t-test), indicating 
partial intracranial origin (Figure 2B). The blood-derived fraction could have two sources: the 
initial bleed itself, and increased transfer from the circulation via a more permeable BBB. If 
the initial bleed was the predominant source of plasma proteins in the CSF, one would expect 
a significant negative correlation between sampling time and Qalb; however this was not 
present (Pearson correlation coefficient = -0.045, p=0.826). In support of increased transfer 
from the circulation across a compromised BBB, there was a significant increase in BBB 
permeability in the high CSF Hpx group as evidenced by a raised Qalb (two-fold, p=0.033, 
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unpaired t-test, Figure 2C). Hence, the predominant source of increased CSF Hpx associated 
with poor outcome was intrathecal, with some derived from the circulation.  
 
Saturation of heme-Hpx uptake following SAH. The high CSF Hpx suggested saturation of 
heme-Hpx uptake. In order to look for this, SAH CSF was examined for the presence of 
heme-Hpx complexes. Sufficient CSF from one patient in Clinical Study 1 was available for 
UPLC analysis to detect bound heme; in this patient, who had a high CSF Hpx level 
(98.5µg/L), a substantial amount of heme was bound to Hpx and albumin (Inset in Figure 3A, 
Figure I online-only Data Supplement, peak at 4.5min). In seven other high-grade SAH 
patients, with repeated CSF sampling (Clinical Study 2), bound heme was found at all time 
points, confirming rapid saturation of heme-Hpx uptake, up to at least day 13 after SAH 
(Figure 3A). 
 
Free heme after SAH. In the same seven patients from Clinical Study 2, unbound heme was 
assayed by performing UPLC before and after adding recombinant Hpx to the CSF sample, 
the difference in area-under-the-curve representing unbound heme. All samples tested 
showed an increase in the peak for bound heme when pre-incubated with recombinant Hpx, 
indicating the presence of free, unbound heme in the CSF, up to at least day 13 after SAH 
(Figure 3B). 
 
Evidence for efflux of free heme from the brain. After SAH, a small and lipophilic 
molecule such as heme can theoretically diffuse out of the brain into the bloodstream down a 
steep concentration gradient across the BBB. There was a significant drop in serum Hpx after 
SAH (mean of 0.72mg/ml in controls versus 0.55mg/ml after SAH, p=0.002, unpaired t-test, 
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Figure 3C). This decrease was confined to patients with the highest Qalb, in whom BBB 
permeability to heme would be the highest (p=0.04, unpaired t-test, Figure 3D). 
 
Discussion 
 
This is the first study to characterise the intrathecal CD91-Hpx system in control individuals 
and following SAH. Intrathecal production is likely to be the main source of CSF Hpx, with 
only about one tenth being derived from the circulation. Hpx is known to be produced within 
the brain and CD91 is not expressed by cerebral endothelium5, 8, so receptor-mediated 
transport of Hpx into the brain is unlikely, but cannot be excluded. Still, CSF Hpx was 10-
fold lower compared to serum, suggesting that the brain has a comparatively lower heme-
binding capacity.  
 
After SAH, the CD91-Hpx scavenging system is active in the brain, since CD91 significantly 
correlated with iron deposition. CSF Hpx had a bimodal pattern after SAH. Despite similar 
bleed size and severity, high CSF Hpx patients had a poorer outcome, with higher DCI rates 
and higher mRS scores. This needs replication since CSF Hpx may be of clinical utility as a 
prognostic marker. The GOS was not significantly different between individuals with normal 
and high CSF Hpx; however, such a discrepancy between GOS and mRS has been noted after 
SAH before, 9 and may be related to the higher number of scoring categories of the mRS 
being able to differentiate neurological sequelae with greater subtlety. In addition mRS is a 
stroke outcome scale, more akin to SAH, while GOS was developed as a scale for use in 
traumatic head injury. 
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The elevation of CSF Hpx, and its relationship to outcome, is intriguing and the mechanism 
is not clear. Hpx has been reported to be neuroprotective10, and therefore CSF Hpx is not 
assumed to be toxic. However it is also possible that when CSF Hpx is too high, it becomes 
deleterious by binding heme, preventing its efflux from the brain and resulting in intracellular 
heme/iron overload, which may be toxic to neurones/glia. Another potential explanation is 
that events after SAH, such as saturation of heme-Hpx uptake and/or inflammation, result in 
high CSF Hpx and poor outcome, which are therefore indirectly associated. Clearly further 
mechanistic studies are needed.  
 
CSF Hpx had two sources: (1) accumulation from an intrathecal origin (as indicated by a 
three-fold rise in the Hpx intrathecal index); (2) increased transfer from the circulation 
(supported by a two-fold higher Qalb). Accumulation of brain-derived Hpx after SAH may 
occur as a result of increased synthesis or decreased CD91-mediated scavenging. Increased 
synthesis may be secondary to the host inflammatory response, since the Hpx promoter is IL-
6 responsive11 and IL-6 levels are elevated in SAH CSF.12  Decreased CD91-mediated 
scavenging may be due to plateauing in heme-Hpx uptake since heme and Hpx were detected 
simultaneously in the CSF. Also, since CD91 has multiple ligands, it is possible that there is 
competition for CD91 from other ligands, such as ApoE13. Interestingly, CSF ApoE is known 
to decrease following SAH13 and low CSF ApoE associates with a poor outcome,14 similar to 
patients with high CSF Hpx in this study. 
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Figures 
 
 
Figure 1 A, Albumin (Qalb) and hemopexin (Qhpx) quotients in controls; B-D, Post-mortem 
study; B, CD91 immunohistochemistry in control human brain; scale bar: 100µm; C, Perls 
staining for iron deposition in SAH and control cases; D, Correlation of CD91 with 
intracellular iron after SAH; red and black data points denote SAH tissue sections with and 
without blood clot respectively. 
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Figure 2 A-C, CSF Hpx from controls and SAH patients; A DCI, GOS and mRS in high 
versus normal CSF Hpx SAH patients; B-C, Hpx intrathecal index and albumin quotient of 
high versus normal CSF Hpx SAH patients. 
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Figure 3 A-B, Bound and free heme at day 0 up to 8-13 days post-ictus. Inset shows UPLC 
analysis of a high Hpx CSF: a substantial peak for Hpx/albumin-bound heme is observed at 
4.5min (arrow); C-D, Heme efflux to the periphery after SAH. C, Serum Hpx in controls and 
SAH patients. D, Variation of serum Hpx level with albumin quotient. 
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SUPPLEMENTAL MATERIAL 
The heme-hemopexin scavenging system is active in the brain, and associates with 
outcome after subarachnoid hemorrhage 
 
Supplemental tables 
 
Table I Demographics of Clinical Study 1 
 SAH Controls 
Number 30 20 
Age (years) 52.1 ± 9.6 41.3 ± 16.6 
Sex (% female) 68 70 
Presentation Glasgow Coma Scorea 11 ± 4.2  
Fisher gradea 3.7 ± 0.7  
WFNS scorea 2.9 ± 1.5  
DCI: clinical evidence (%)a 23.1  
DCI: CT evidence (%)a 23.1  
DCI: clinical & CT evidence (%)a 30.7  
6 month Glasgow Outcome Scoreb 3.5 ± 1.7  
6 month Modified Rankin Scorec 3.0 ± 2.5  
Days post-ictus when sample taken  3.9 ± 2.6  
 
Values represent mean ± standard deviation where applicable. Data available for 26a, 28b and 
25c patients. Abbreviations: CT: Computed Tomography; DCI: Delayed Cerebral Ischaemia; 
WFNS: World Federation of Neurological Surgeons 
 
Table II Demographics of clinical study 2 
Number 7 
Age in years 59.9 ± 17.8 
Sex (% female) 40 
Presentation Glasgow Coma Score 9.7 ± 3.7 
Fisher grade 3.9 ± 0.4 
WFNS score 3.0 ± 1.3 
DCI: clinical evidence 2/7 
DCI: CT evidence 1/7 
DCI: clinical & CT evidence 2/7 
3 month Modified Rankin Score 2.2 ± 1.5 
 
Values represent mean ± standard deviation where applicable. Abbreviations: CT: Computed 
Tomography; DCI: Delayed Cerebral Ischaemia; WFNS: World Federation of Neurological 
Surgeons 
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Table III Characteristics of patients by CSF Hpx concentration 
 Normal CSF Hpx 
High CSF 
Hpx p value 
Number of cases 21 9  
CSF Hpx concentration (µg/ml) 18.3 ± 8.0 133.8 ± 42.2 1.4 x 10-7* 
DCI: clinical evidence (%)a 11 57 0.028* 
DCI: CT evidence (%)a 11 57 0.028* 
DCI: clinical & CT evidence (%)a 21 57 0.101 
6 month Modified Rankin Scoreb 2.4 ± 2.2 5.0 ± 2.4 0.025* 
6 month Glasgow Outcome Scorec 3.9 ± 1.5 2.5 ± 1.6 0.122 
Presentation GCS 11.7 ± 3.6 9.0 ± 5.4 0.248 
Fisher grade 3.6 ± 0.8 3.9 ± 0.4 0.497 
WFNS score 2.7 ± 1.5 3.3 ± 1.6 0.395 
Days post-ictus sample taken 4.4 ± 2.6 2.6 ± 2.2 0.120 
CSF Hb concentration (µmol/l)d 0.69 ± 0.93 0.20 ± 0.18 0.219 
Blood clot: mean voxel radiodensitye 103.1 ± 11.1 110.2 ± 6.3 0.198 
Age in years 51.1 ± 9.0 54.4 ± 10.0 0.388 
Sex (% female) 55 89 0.207 
 
Values represent mean ± standard deviation where applicable. Data available for 26a, 25b, 
28c, 23d and 20e patients. Statistical analysis employed Mann-Whitney test (for CSF Hpx, 
Fisher, WFNS), Fisher exact test (for DCI and gender) and unpaired test for the rest. 
Abbreviations: CSF: Cerebrospinal Fluid; CT: Computed Tomography; DCI: Delayed 
Cerebral Ischaemia; Hb: Haemoglobin; Hpx: Haemopexin; WFNS: World Federation of 
Neurological Surgeons 
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Supplemental figures 
 
 
Figure I The CD91 system is saturated following SAH. UPLC trace at 415nm to identify 
bound heme related peaks from the CSF of a patient with high CSF Hpx; a substantial peak 
for Hpx and albumin bound heme is observed at 4.5min
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Supplemental Methods 
 
Clinical study 1 (Main study) 
Admission computed tomography (CT) images were available for 20 patients, and 
quantitative analysis of blood clot average voxel radiodensity, as a surrogate of bleed size, 
was performed as previously described.1 Clinical information regarding delayed cerebral 
ischaemia (DCI) was available for 26 patients. Clinical DCI was defined as the onset of a 
new focal neurological deficit or a two point drop in the Glasgow Coma Score in the absence 
of rebleeding, hydrocephalus, metabolic abnormalities or seizure activity.2 Computed 
tomography (CT) evidence of DCI consisted of low attenuation on unenhanced CT of the 
brain consistent with ischaemia, irrespective of clinical state, which was not deemed to be a 
result of surgical intervention. CSF in patients with SAH was obtained from external 
ventricular drains. Control participants were patients with non-inflammatory / non-
haemorrhagic conditions who underwent lumbar puncture and were subsequently found to 
have normal CSF with respect to protein, glucose, cell count, cytology, albumin CSF/serum 
quotient and isoelectric focusing for oligoclonal bands. Samples were collected with 
Research Ethical Committee approval (04/Q2707/236 and 07/H0304/71). Serum and CSF 
Hpx levels were analysed by enzyme-linked immunosorbent assay (ELISA) using 
commercially available kits, as per kit instructions (AssayMax Human Hemopexin, EH1001-
1 and EH2001-1 respectively, AssayPro, MO, USA). The upper and lower limits of the CSF 
Hpx reference range was calculated by adding and subtracting two standard deviations 
around the mean. Serum and CSF albumin were analysed by rate nephelometry on a 
Beckman Coulter IMMAGE immunochemistry system. Sufficient CSF was available from 23 
patients with SAH to perform derivative spectrophotometry for quantification of Hb as 
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previously described, 1 and from one patient to perform heme measurements using ultra-high 
performance liquid chromatography (UPLC) as described below. 
 
Clinical study 2 
Clinical study 1 did not produce large enough CSF volumes for UPLC analysis of heme 
concentration which needed 400uL. Therefore, in a second study, serial CSF samples were 
obtained from seven additional patients with high grade SAH (Fisher grade III-IV) admitted 
to the Southampton centre, requiring prolonged external ventricular drainage, under research 
approval 12/SC/0666. The characteristics of these patients are shown in Table II in the 
online-only Data Supplement.  
Ultra-high performance liquid chromatography (UPLC). Size-exclusion UPLC was used 
to separate components by size. Peaks were monitored at 415 nm wavelength to exclude non-
heme related peaks while differentiating bound heme from free and bound Hb. Heme 
quantitation was performed by reading against a standard curve. A Hb standard solution was 
prepared from commercially-available lyophilized human Hb (Sigma). This was reconstituted 
to 1 g/L in diluent (9 g/L NaCl, 10 mM EDTA). The concentration of the standard Hb 
solution was verified independently by spectrophotometric quantitation of derivatized heme 
at 570 nm using a Hemocue™ (Hemocue, Sweden). A concentration series of 9 data points 
from 0 to 1 mg/ml was prepared from the standard solution and measured at 415 nm on the 
UPLC. Accuracy of the standard curve was determined to be 3.3% using a Hb control. CSF 
samples were saturated with 250 µg/ml Hpx (Sigma) to detect total heme, or measured neat 
to detect bound heme. 50µl of each sample was loaded onto the UPLC column using a 
running buffer consisting of 50 mM Tris and 150 mM NaCl, at pH 7.5. Absorbance was 
measured at 415 nm and the area under the curve calculated and quantitated against the 
standard curve. Free heme was calculated by subtracting bound heme from total heme. Each 
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assay run was controlled using an in-house hemoglobin-haptoglobin standard measured at 
three concentration levels; 200 µg/ml, 10 µg/ml and 1 µg/ml to cover the dynamic range of 
the assay, with precision of 1.9%, 16.1% and 36.3% respectively.  
 
Post-mortem study 
Post-mortem formalin-fixed paraffin-embedded tissue from a different set of SAH (n=7) and 
control (n=5) cases was obtained from the University Hospital Southampton NHS Foundation 
Trust as part of the UK Brain Archive Information Network (BRAIN UK) which is funded by 
the Medical Research Council (Research Ethical Committee approval 14/SC/0098). At the 
age of death after SAH, patients had a mean age of 57 years (range 42 to 71). 71% were 
females. The location of the aneurysm varied (including middle cerebral, posterior 
communicating and basilar arteries). Hence the location of the clot varied; most sections were 
taken from the neocortex apart from a cerebellar and brainstem case. Control cases were 
matched for age (mean age of 53 years, range 35 to 82) and sex (80% females), did not die 
from neurological causes, and were selected carefully to exclude inflammatory, haemorrhagic 
or neurodegenerative pathology. Histology & immunohistochemistry. Sections were cut at 
4µm thickness. To detect the presence of iron deposition, Perls Prussian blue staining was 
performed. Sections were dewaxed, rehydrated, and treated for 10 minutes with freshly 
prepared Perls reagent (2% potassium ferrocyanide and 2% HCl mixed in a 1:1 ratio) for 30 
minutes. Then the slides were counterstained with 0.1% neutral red, dehydrated and mounted 
in DePeX. For detection of the CD91 Hpx receptor, immunohistochemistry was performed on 
paraffin tissue. Sections were dewaxed, rehydrated, pressure cooked in citrate buffer to 
retrieve antigen, incubated with anti-CD91 antibody (ab92544, Abcam, Cambridge, UK) at 
1:1000 dilution overnight, followed by incubation with biotin-conjugated secondary antibody. 
Development was performed using the ABC method and 0.05% 3,3`-diaminobenzidine. 
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Sections were finally counterstained with haematoxylin, dehydrated and mounted in DePeX. 
Sections incubated in the absence of the primary antibody were included as negative controls, 
and all sections were immunolabelled together to ensure comparability of staining. 
Quantification. For each case, ten images were digitally acquired from grey matter in a 
ribbon following the most prominent sulcus in each section, using a camera mounted on a 
light microscope at magnification x20. The images were analysed with Image J (version 1.47, 
NIH US) to obtain a protein load defined as the percentage area stained of total area 
examined (%). Perls staining severity index was quantified as described previously.3 
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